Interestingly, cancer cells are specially sensitive to lysosomal-mediated programmed cell death (LM-PCD) through the cytosolic activation of pro-apoptotic (i.e., Bid) and the inactivation of anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-XL, and Mcl1) by lysosomal proteases [191,221,222], thus potentially providing novel therapeutical opportunities for cancer treatment [155,179,223,224,225]. This evidence concerns the gene BCL2 and cancer.